David Rusnak, BioAgilytix’s Director of Bioanalytical Operations, contributes to this article by Genetic Engineering & Biotechnology News (GEN) discussing how cell-based assays have become a mainstay of drug development, addressing new concerns raised by the advent of biologics – including the difficulties inherent in characterizing drug efficacy and patient safety in the context of immunogenicity.
Services
Platforms